US to loosen marijuana rules in major shift for $47 billion industry

The U.S. Department of Justice will loosen marijuana restrictions and begin proceedings on June 29 to reclassify cannabis as less dangerous, a major regulatory shift for the roughly $47 billion industry. The change should reduce research barriers, ease tax burdens, and improve funding access, benefiting U.S.-listed cannabis companies such as Canopy Growth, Tilray Brands, and Trulieve Cannabis, whose shares jumped 6% to 13%. It does not legalize marijuana nationwide, but it materially improves the sector’s federal operating environment.

Analysis

This is more important for capital formation than for near-term revenue. The first-order move is a sentiment rerate, but the second-order effect is that lower federal friction reduces the cost of equity for the sector: cannabis names have been priced as if their earnings are structurally unreinvestable, and that discount can compress quickly when lenders and institutions are allowed to underwrite more comfortably. The biggest beneficiaries are the balance-sheet survivors with enough scale to refinance into growth, while the weakest operators will likely see the opposite effect as cheaper capital exposes how little operating leverage they actually have.

The clearest relative winner is TLRY versus CGC, because this change rewards companies with optionality across medical, consumer, and pharmaceutical-like channels rather than pure retail footprint. That matters because the market will eventually differentiate between “rescheduling beneficiaries” and “credible industrial platforms”; names with higher gross margin mix and broader distribution can convert regulatory relief into EBITDA faster. A less obvious winner is ancillary services and packaging/logistics providers, which should see a step-up in contract activity as mainstream retailers and state systems become more willing to engage.

The main risk is timing mismatch. The headline can drive a short squeeze over days, but the actual legal process still stretches over months, and any delay, procedural challenge, or congressional pushback can unwind part of the move. Longer term, the overhang is that rescheduling helps economics but does not fully solve interstate commerce, banking normalization, or 280E-style tax distortions unless policy goes further; that caps the multiple expansion unless investors start pricing a broader federal reset.

Consensus is probably underestimating how much of the move is a funding event rather than a consumption event. If lower borrowing costs and improved access to institutional capital arrive before demand growth, incumbents can use the window to delever, cut cash burn, and consolidate weaker peers; that can support winners even if end-market growth remains only mid-teens. The trade, therefore, is less about a one-day pop and more about identifying which names can translate policy relief into durable per-share value creation over the next 2-4 quarters.

Key Decisions for Investors

• Go long TLRY on pullbacks over the next 1-2 sessions; target a 2-3 month trade on multiple expansion plus improved financing access, with a tighter stop if the stock gives back more than half of the post-news gap.
• Trade CGC as a lower-quality beneficiary versus TLRY: only take it on a relative-value basis, not outright, because policy relief helps the sector but does not fix weaker unit economics; pair long TLRY / short CGC for a 1-3 month spread trade.
• Buy a small basket long in the cannabis complex with a focus on names that can refinance or cut interest expense; size it as a catalyst trade, not a long-duration compounder, because the legal process still carries headline risk over the next 3-6 months.
• Use upside calls instead of common stock for momentum capture in TLRY or a basket ETF if liquidity allows; the asymmetry is best over the next 2-6 weeks while the market reprices the probability of full federal easing.
• Fade the move only if the stocks extend into a parabolic squeeze without confirmation from policy milestones; otherwise stay with the trend because the next catalyst path is more likely to be incremental-positive than negative in the near term.